Drug intelligence / Profile preview

CS-2028

Development stage: Preclinical
Lead developer: CanSino Biologics
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**CS-2028** is a preclinical multivalent pneumococcal conjugate vaccine developed by CanSino Biologics for prevention of pneumococcal disease caused by *Streptococcus pneumoniae*. The candidate is intended to induce protective immune responses against multiple pneumococcal serotypes through conjugated pneumococcal antigens; its specific serotype composition, carrier protein, adjuvant, formulation, and administration route have not been publicly disclosed.

Beyond the preview

Go deeper on CS-2028.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS-2028.

Explore the full profile